Brightgene Bio-medical Technology Co., Ltd.

This study is testing whether a new investigational drug called BGM0504 works as well as or better than an existing weight loss medication, tirzepatide, for adults with obesity. About 90 participants will receive one of the two drugs for 26 weeks. Researchers will measure changes…

This early-stage study is testing a new oral medication called BGM0504 for weight management in non-diabetic adults who are overweight or obese. Researchers will give 80 participants either the active tablet or a placebo daily to assess safety, how the body processes the drug, an…

This is an early-stage study to check the safety and basic effects of a new drug called BGM1812 in Chinese adults. It will involve 60 healthy and overweight participants who will receive injections of the drug or a placebo. Researchers will monitor for side effects and see how th…

This study aims to see if a new drug called BGM0504 works as well or better than an established drug (semaglutide) for controlling type 2 diabetes. Both drugs are given as a weekly injection on top of the standard pill, metformin. The trial will involve 477 adults in Indonesia an…

This is an early-stage study to check the safety and how the body processes a new oral drug called BGM0504. It will involve 75 healthy, overweight, or obese Chinese adults who do not have diabetes. Researchers will give participants either the drug or a placebo (inactive pill) an…

This early-stage study is testing a new injection called BGM1812 in healthy adults who range from normal weight to obese. Researchers want to understand how the body processes the drug, check its safety, and see if it affects body weight. The study will involve 60 participants re…

This early-stage study aims to see if two different injection pens for the same experimental obesity drug, BGM0504, work the same way in the body. It will involve 144 overweight or obese adults who will receive a single injection. The main goal is to compare how the drug from a m…